Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

41. Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated (...) : February 22, 2019 Project Number: RC1069-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of hydrogel spacers for patients with prostate cancer? What is the cost-effectiveness of hydrogel spacers for patients with prostate cancer? Key Message Three systematic reviews, one randomized controlled trial (described within two eligible reports), seven cohort studies, two economic evaluations

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

42. Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines

Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness (...) and Guidelines Last updated: February 5, 2019 Project Number: RB1307-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of combination therapy in adults with any stage of breast cancer? What are the evidence-based guidelines associated with the use of combination therapy in adults with any stage of breast cancer? Key Message Two systematic reviews (one with a meta-analysis), 15 non-randomized studies, and one

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

43. Stereotactic Body Radiotherapy for Oligometastatic Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Stereotactic Body Radiotherapy for Oligometastatic Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Stereotactic Body Radiotherapy for Oligometastatic Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Stereotactic Body Radiotherapy for Oligometastatic Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Stereotactic Body Radiotherapy for Oligometastatic Cancer: A Review of Clinical Effectiveness and Cost (...) -Effectiveness Last updated: February 6, 2019 Project Number: RC1071-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of stereotactic body (or stereotactic ablative) radiotherapy for the treatment of oligometastatic cancer? What is the cost effectiveness of stereotactic body (or stereotactic ablative) radiotherapy for the treatment of oligometastatic cancer? Key Message Clinical evidence

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

44. Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines

Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines | CADTH.ca Find the information you need Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Last updated: February 6, 2019 Project Number: RB1305-000 Product Line: Research Type: Devices and Systems Report Type: Summary (...) of Abstracts Result type: Report Question What are the evidence-based guidelines regarding sample selection for biomarker testing to inform treatment decisions in adults with breast cancer? Key Message Four evidence-based guidelines were identified regarding sample selection for biomarker testing in adults with breast cancer. Files Rapid Response Summary of Abstracts Published : February 6, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

45. Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review

Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review | CADTH.ca Find the information you need Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Last updated: May 3, 2019 Project Number: RC1104-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What (...) are the experiences and perspectives of breast cancer patients, their caregivers and their health care providers with respect to breast cancer surgical care in rural areas? To ensure the relevance of the analysis to the objectives of the primary research question, a secondary set of research questions was explored during data extraction and analysis:a) How do people with breast cancer, and their families, experience travelling for breast cancer surgical care?b) What is the meaning and impact of receiving breast

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

46. Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical (...) Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 22, 2019 Project Number: RC1102-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of intraoperative imaging with mammography for breast cancer surgery? What is the cost-effectiveness of intraoperative imaging with mammography for breast cancer surgery? What are the evidence-based guidelines regarding intraoperative imaging

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

47. Assessment and management of bone health in women with oestrogen receptor?positive breast cancer receiving endocrine therapy: position statement summary

Assessment and management of bone health in women with oestrogen receptor?positive breast cancer receiving endocrine therapy: position statement summary Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page (...) doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary Mathis Grossmann, Sabashini K Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks and Helena J Teede Med J Aust 2019; 211 (5

2019 MJA Clinical Guidelines

48. Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V

Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Rucaparib (Ovarialkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A19-22 Rucaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-22 Version 1.0 Rucaparib (ovarian cancer) 29 May 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Rucaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 26

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

49. Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report

Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report 1 Translation of the key statement of the rapid report N17-04 Interstitielle Low-Dose-Rate-Brachytherapie beim lokal begrenzten Prostatakarzinom (Version 1.0; Status: 19 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Extract IQWiG Reports – Commission No. N17-04 Interstitial low-dose-rate brachytherapy for localized prostate cancer 1 Extract of rapid report N17-04 Version 1.0 Brachytherapy for prostate cancer 19 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Interstitial low-dose-rate brachytherapy for localized prostate cancer Commissioning agency: Federal Joint Committee Commission awarded

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

50. ALK Inhibitors for Non–Small Cell Lung Cancer

ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer | CADTH.ca Find the information you need ALK Inhibitors for Non–Small Cell Lung Cancer ALK Inhibitors for Non–Small Cell Lung Cancer Last updated: February 20, 2019 Project Number: HE0017-000 Product Line: Technology Review Result type: Report Lung cancer is the second-most commonly diagnosed cancer in both men and women, and is the leading cause of cancer deaths in Canada. Rearrangement (...) of the Anaplastic Lymphoma Kinase (ALK) gene drives the development of about 5% of non–small cell lung cancers (NSCLC). Inhibitors of ALK can effectively delay progression of these malignancies and are the treatment of choice in the first-line and subsequent line settings. This drug class is expanding and new products are poised to enter the market. Reviews of the comparative clinical and cost-effectiveness of ALK inhibitors, and of guidelines pertaining to their use, were requested by Canadian decision-makers

2019 Publication 4890897

51. Low Dose Naltrexone for the Treatment of Any Cancer Type: Clinical Effectiveness and Guidelines

Low Dose Naltrexone for the Treatment of Any Cancer Type: Clinical Effectiveness and Guidelines Low Dose Naltrexone for the Treatment of Any Cancer Type: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Low Dose Naltrexone for the Treatment of Any Cancer Type: Clinical Effectiveness and Guidelines Low Dose Naltrexone for the Treatment of Any Cancer Type: Clinical Effectiveness and Guidelines Last updated: January 8, 2019 Project Number: RB1295-000 Product Line (...) : Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of low dose naltrexone for the treatment of any cancer type? What are the evidence-based guidelines associated with the use of low dose naltrexone for the treatment of any cancer type? Key Message No relevant literature was found regarding low dose naltrexone for the treatment of any cancer type. Files Rapid Response Summary of Abstracts Published : January 8, 2019 Related Content

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

52. HPV Testing for Primary Cervical Cancer Screening

HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening | CADTH.ca Find the information you need HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening Published on: March 26, 2019 Project Number: OP0530-000 Product Line: Result type: Report Worldwide, cervical cancer is one of the most frequently diagnosed cancers; however, the incidence of cervical cancer has been decreasing in the past three decades (...) , largely due to routine screening with cytology. HPV is the major risk factor for the development of cervical cancer, with 99% of cervical cancer being associated with HPV. It is one of the most common sexually transmitted infections in the world and about three out of every four sexually active Canadians will have at least one HPV infection at some point in their lives. In view of the anticipated higher sensitivity of HPV testing, some experts and stakeholders have called for HPV testing to be used

2019 CADTH - Optimal Use

53. Reduction of Red and Processed Meat Intake and Cancer Mortality and Incidence: A Systematic Review and Meta-analysis of Cohort Studies. (PubMed)

Reduction of Red and Processed Meat Intake and Cancer Mortality and Incidence: A Systematic Review and Meta-analysis of Cohort Studies. Cancer incidence has continuously increased over the past few centuries and represents a major health burden worldwide.To evaluate the possible causal relationship between intake of red and processed meat and cancer mortality and incidence.Embase, Cochrane Central Register of Controlled Trials, Web of Science, CINAHL, and ProQuest from inception until July 2018 (...) and MEDLINE from inception until April 2019 without language restrictions.Cohort studies that included more than 1000 adults and reported the association between consumption of unprocessed red and processed meat and cancer mortality and incidence.Teams of 2 reviewers independently extracted data and assessed risk of bias; 1 reviewer evaluated the certainty of evidence, which was confirmed or revised by the senior reviewer.Of 118 articles (56 cohorts) with more than 6 million participants, 73 articles were

2019 Annals of Internal Medicine

54. Patterns of Red and Processed Meat Consumption and Risk for Cardiometabolic and Cancer Outcomes: A Systematic Review and Meta-analysis of Cohort Studies. (PubMed)

Patterns of Red and Processed Meat Consumption and Risk for Cardiometabolic and Cancer Outcomes: A Systematic Review and Meta-analysis of Cohort Studies. Studying dietary patterns may provide insights into the potential effects of red and processed meat on health outcomes.To evaluate the effect of dietary patterns, including different amounts of red or processed meat, on all-cause mortality, cardiometabolic outcomes, and cancer incidence and mortality.Systematic search of MEDLINE, EMBASE (...) GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.Eligible studies that followed patients for 2 to 34 years revealed low- to very-low-certainty evidence that dietary patterns lower in red and processed meat intake result in very small or possibly small decreases in all-cause mortality, cancer mortality and incidence, cardiovascular mortality, nonfatal coronary heart disease, fatal and nonfatal myocardial infarction, and type 2 diabetes. For all-cause, cancer

2019 Annals of Internal Medicine

55. Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials. (PubMed)

Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials. Few randomized trials have evaluated the effect of reducing red meat intake on clinically important outcomes.To summarize the effect of lower versus higher red meat intake on the incidence of cardiometabolic and cancer outcomes in adults.EMBASE, CENTRAL, CINAHL, Web of Science, and ProQuest from inception to July 2018 and MEDLINE from inception to April 2019, without (...) or no effect on all-cause mortality (hazard ratio [HR], 0.99 [95% CI, 0.95 to 1.03], cardiovascular mortality (HR, 0.98 [CI, 0.91 to 1.06]), and cardiovascular disease (HR, 0.99 [CI, 0.94 to 1.05]). That trial also provided low- to very-low-certainty evidence that diets lower in red meat may have little or no effect on total cancer mortality (HR, 0.95 [CI, 0.89 to 1.01]) and the incidence of cancer, including colorectal cancer (HR, 1.04 [CI, 0.90 to 1.20]) and breast cancer (HR, 0.97 [0.90 to 1.04

2019 Annals of Internal Medicine

56. Metastatic Non-Small-Cell Lung Cancer

Metastatic Non-Small-Cell Lung Cancer Updated version published 18 September 2019 by the ESMO Guidelines Committee © European Society for Medical Oncology 2019. All rights reserved. 1 CLINICAL PRACTICE GUIDELINES Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † Originally published in 2018 – Ann Oncol (2018) 29 (suppl 4): iv192–iv237 D. Planchard 1 , S. Popat 2 , K. Kerr 3 , S. Novello 4 , E. F. Smit 5 , C. Faivre-Finn 6 , T. S (...) . Mok 7 , M. Reck 8 , P. E. Van Schil 9 , M. D. Hellmann 10 & S. Peters 11 , on behalf of the ESMO Guidelines Committee* 1 Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France; 2 Royal Marsden Hospital, London; 3 Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK; 4 Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy; 5 Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands; 6 Division

2019 European Society for Medical Oncology

57. Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer

Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original

2019 Health Canada - Drug and Health Product Register

58. Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive Drug Approval Package: ROZLYTREK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ROZLYTREK Company: Genentech Application Number: 212725, 212726 Approval Date: 08/15/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

59. Thyroid Cancer

Thyroid Cancer Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † S. Filetti 1 , C. Durante 1 , D. Hartl 2 , S. Leboulleux 3 , L.D. Locati 4 , K. Newbold 5 , M.G. Papotti 6 , A. Berruti 7 , on behalf of the ESMO Guidelines Committee* 1 Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy; 2 Department of Head and Neck Oncology, Gustave Roussy and Université Paris Saclay, Villejuif; 3 Department of Nuclear (...) : clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: February 2008, last update September 2019. This publication supersedes the previously published version—Ann Oncol 2012; 23 (Suppl. 7): vii110–vii119. Running header: ESMO Clinical Practice Guidelines thyroid cancer Word count: 11 701 (excluding key message, references, tables & figures) Key words: papillary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, management Key message (online only): ©

2019 European Society for Medical Oncology

60. New eUpdate featuring treatment algorithm for Early Colon Cancer

New eUpdate featuring treatment algorithm for Early Colon Cancer eUpdate - Early Colon Cancer Treatment Recommendations Algorithm | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.​ Connect with ESMO (...) with news about ESMO guidelines, including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading ESMO Guidelines Slide Sets Quick and easy access to the essential content of the guidelines – PowerPoint slides and PDFs including algorithms, figures and tables – free to download Breast Cancer Early Breast Cancer • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) • Prevention and Screening in BRCA Mutation Carriers and Other

2019 European Society for Medical Oncology